Daniel M. Blumenthal, MD, MBA; Dana P. Goldman, PhD; Anupam B. Jena, MD, PhD
Note: Dr. Goldman is founder of, and Drs. Jena and Blumenthal are external consultants at, Precision Health Economics, a company providing consulting services to the life sciences industry. A prior study of PCSK9 inhibitors, conducted by the authors, was funded by Precision Health Economics through a grant from Amgen. No compensation was provided by the life sciences industry for the current work.
Grant Support: By the Office of the Director, National Institutes of Health (NIH Early Independence Award, grant 1DP5OD017897-01; Dr. Jena), and the National Institute on Aging (grant 5P01AG033559; Dr. Goldman).
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-1847.
Requests for Single Reprints: Anupam B. Jena, MD, PhD, Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115; e-mail, email@example.com.
Current Author Addresses: Dr. Blumenthal: Massachusetts General Hospital, Cardiology Division, 55 Fruit Street, Yawkey Building, Suite 5B, Boston, MA 02114.
Dr. Goldman: Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, 650 Childs Way, RGL 214, Los Angeles, CA 90089.
Dr. Jena: Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115.
Author Contributions: Conception and design: D.M. Blumenthal, D.P. Goldman, A.B. Jena.
Analysis and interpretation of the data: D.M. Blumenthal, A.B. Jena.
Drafting of the article: D.M. Blumenthal, D.P. Goldman, A.B. Jena.
Critical revision of the article for important intellectual content: D.M. Blumenthal, D.P. Goldman, A.B. Jena.
Final approval of the article: D.M. Blumenthal, D.P. Goldman, A.B. Jena.
Obtaining of funding: A.B. Jena.
Administrative, technical, or logistic support: A.B. Jena.
Collection and assembly of data: A.B. Jena.
Learn more about subscription options.
Register Now for a free account.
Blumenthal DM, Goldman DP, Jena AB. Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals. Ann Intern Med. 2017;166:219-220. doi: 10.7326/M16-1847
Download citation file:
Published: Ann Intern Med. 2017;166(3):219-220.
Published at www.annals.org on 13 December 2016
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only